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Introduction {#bjs11283-sec-0005}
============

An increasingly aggressive surgical approach in patients with colorectal cancer liver metastases (CRLM) has led to higher numbers of long‐term survivors. However, 80--90 per cent of patients with CRLM are not amenable to surgery at diagnosis[1](#bjs11283-bib-0001){ref-type="ref"}, [2](#bjs11283-bib-0002){ref-type="ref"}, [3](#bjs11283-bib-0003){ref-type="ref"}, [4](#bjs11283-bib-0004){ref-type="ref"} and liver metastases remain the principal site of fatal colorectal cancer[5](#bjs11283-bib-0005){ref-type="ref"}, [6](#bjs11283-bib-0006){ref-type="ref"}, [7](#bjs11283-bib-0007){ref-type="ref"}, [8](#bjs11283-bib-0008){ref-type="ref"}. Secondary resection and/or thermal ablation of primarily unresectable CRLM following systemic treatment may prolong survival or be curative in some patients[4](#bjs11283-bib-0004){ref-type="ref"}, [9](#bjs11283-bib-0009){ref-type="ref"}, [10](#bjs11283-bib-0010){ref-type="ref"}, [11](#bjs11283-bib-0011){ref-type="ref"}, [12](#bjs11283-bib-0012){ref-type="ref"}, [13](#bjs11283-bib-0013){ref-type="ref"}, [14](#bjs11283-bib-0014){ref-type="ref"}, [15](#bjs11283-bib-0015){ref-type="ref"}, [16](#bjs11283-bib-0016){ref-type="ref"}. However, there is uncertainty surrounding the best treatment combination to achieve downsizing of the metastatic lesions for resection, as few trials have specifically addressed this[17](#bjs11283-bib-0017){ref-type="ref"}. In the absence of a clear definition of unresectability, effective treatments for downsizing of metastatic liver tumours are difficult to evaluate objectively. Many factors influence the decision to perform these procedures, and studies focusing on secondary resection/ablation after downsizing treatment have used very heterogeneous inclusion criteria[15](#bjs11283-bib-0015){ref-type="ref"}, [18](#bjs11283-bib-0018){ref-type="ref"}, [19](#bjs11283-bib-0019){ref-type="ref"}. Few studies on the effects of liver‐directed therapy on the resectability of CRLM have been undertaken[20](#bjs11283-bib-0020){ref-type="ref"}. Selective internal radiotherapy (SIRT) with yttrium‐90 (^90^Y) labelled microspheres is a liver‐directed therapy that could downsize tumours and render them amenable to surgery[20](#bjs11283-bib-0020){ref-type="ref"}.

In the randomized SIRFLOX trial that compared chemotherapy with chemotherapy plus a single SIRT procedure in patients with CRLM deemed unresectable, the secondary resection rate was low in both arms[21](#bjs11283-bib-0021){ref-type="ref"}. It is possible that this reflects the presence of poor prognostic features unrelated to the extent of liver tumour involvement, such as extrahepatic disease or patient co‐morbidity, or the reluctance of surgeons to operate on the liver following SIRT because of safety concerns[22](#bjs11283-bib-0022){ref-type="ref"}. Hence, the secondary resection rate in SIRFLOX does not provide information on how resectability would have been affected by chemotherapy or chemotherapy plus SIRT in patients otherwise suitable for surgery.

SIRT has yielded encouraging tumour response rates in uncontrolled or small‐scale studies[23](#bjs11283-bib-0023){ref-type="ref"}. In SIRFLOX, the tumour response rate in the liver was approximately 10 per cent higher in the SIRT than in the control arm. Response to chemotherapy had good correlation with secondary resection rates in previous trials[13](#bjs11283-bib-0013){ref-type="ref"}, [14](#bjs11283-bib-0014){ref-type="ref"}, but some patients may remain unresectable owing to the distribution of the CRLM. These aspects are poorly covered by defined resectability criteria used in studies, making image assessment by experienced hepatopancreatobiliary (HPB) surgeons the most reliable tool with which to determine resectability. This approach was first used in the CELIM (Cetuximab in Neoadjuvant Treatment of Non‐Resectable Colorectal Liver Metastases) trial[24](#bjs11283-bib-0024){ref-type="ref"}, where a blinded surgical image review revealed that almost one‐third of patients who were enrolled because their metastases had been deemed unresectable by local assessment were in fact considered candidates for resection on expert review. The proportion of potentially resectable patients increased to 60 per cent after cetuximab‐containing chemotherapy, making CELIM the first study to prove objectively the principle of 'conversion' chemotherapy. To date, no such data exist for interventional treatments such as SIRT that may play a role in conversion of unresectable liver metastases to surgery, and, therefore, this *post hoc* analysis of SIRFLOX data was performed.

Methods {#bjs11283-sec-0006}
=======

The REsect study, a retrospective analysis of the SIRFLOX study patient cohort, was designed to determine the quasi‐objective change in resectability of CRLM from baseline to follow‐up after first‐line treatment with mFOLFOX6 chemotherapy (oxaliplatin, folinic acid and fluorouracil regimen) with or without bevacizumab (control arm) or mFOLFOX6 with or without bevacizumab plus SIRT (SIRT arm) with ^90^Y‐labelled resin microspheres (SIR‐Spheres®; Sirtex Medical, Sydney, New South Wales, Australia).

As REsect relied on existing CT hepatic imaging data from SIRFLOX and no new data were acquired for the analysis, no formal ethics committee approval was needed. The SIRFLOX study was conducted in accordance with the Declaration of Helsinki, and approval was obtained from the relevant institutional review boards for each participating centre. All patients had to provide written informed consent. SIRFLOX had the <http://clinicaltrials.gov> identifier NCT00724503.

Patients {#bjs11283-sec-0007}
--------

All patients who had received first‐line treatment for CRLM in the SIRFLOX study were eligible for inclusion in the REsect study. Patients had to have evaluable CT data at baseline and follow‐up, and have received the allocated treatment. For enrolment in SIRFLOX, patients had to have histologically confirmed adenocarcinoma of the colon or rectum, with or without the primary tumour *in situ*, with proven liver‐dominant metastatic disease. Patients had to be chemotherapy‐naive, have a WHO performance status of 0--1, and a life expectancy of more than 3 months. Predefined stratification factors included the presence of extrahepatic metastases (liver‐only *versus* liver‐dominant metastatic colorectal cancer), hepatic tumour burden (25 per cent or less *versus* more than 25 per cent), intent to use bevacizumab, and treatment centre. The protocol for SIRFLOX, including full details of inclusion and exclusion criteria, has been published previously[25](#bjs11283-bib-0025){ref-type="ref"}.

Treatment and assessment in the SIRFLOX study {#bjs11283-sec-0008}
---------------------------------------------

Patients were randomized in a 1 : 1 ratio to treatment with an mFOLFOX6 regimen alone or to mFOLFOX6 plus SIRT with ^90^Y‐labelled resin microspheres[25](#bjs11283-bib-0025){ref-type="ref"}. Chemotherapy was continued until disease progression. Patients could receive bevacizumab from cycle 1 in the control arm and from cycle 4 onwards in the SIRT arm.

Patients in the SIRT arm had baseline hepatic angiography and a liver‐to‐lung breakthrough nuclear medicine scan to assess suitability to receive SIRT[25](#bjs11283-bib-0025){ref-type="ref"}. The patient\'s body surface area, percentage tumour involvement, and magnitude of liver‐to‐lung shunting were used to determine the activity (GBq) administered. SIRT was given in a single procedure on day 3--4 of cycle 1 or cycle 2 of mFOLFOX6 treatment.

Patients were assessed by CT every 8--12 weeks until hepatic progression. Other follow‐up assessments included clinical assessment[25](#bjs11283-bib-0025){ref-type="ref"} and suitability for liver resection, at every CT time point. All patients were followed up until death, or to the end of the study.

Blinded review of CT scans in REsect {#bjs11283-sec-0009}
------------------------------------

A pool of 14 HPB surgeons were recruited to perform the blinded review. All reviewers viewed a training video (*Video* [*S1*](#bjs11283-supitem-0001){ref-type="supplementary-material"}, supporting information) to ensure consistency in reading the scans. The criterion for resectability was that resection of all visible lesions, with negative margins and a sufficient future liver remnant (FLR) size, was feasible. Baseline and best response follow‐up imaging of 100 randomly selected patients were presented independently to five HPB surgeons to determine the pooled interobserver agreement and validate the analysis. This initial series of assessments was designed to demonstrate the feasibility of the study methodology. The assessments showed good pooled interobserver agreement and provided the rationale for proceeding with three reviewers per case for the remainder of cases.

All reviewers were blinded to clinical data, extent of extrahepatic disease, study arm assignment, and one another\'s assessments. To ensure that assessment was not biased by a reviewer\'s expectations on changes in resectability after treatment, reviewers were also blinded to the timing of CT (baseline *versus* follow‐up). As the objective was to assess the change in technical resectability of liver metastases, reviewers were explicitly instructed to ignore any patient features other than the extent of liver lesions that may have been visible on the CT scan (such as extrahepatic metastases), even if these might affect the decision for, or against, surgery in real life. A patient was deemed to be resectable or unresectable by majority agreement (3 of 5, or 2 of 3 surgeons: at least 60 per cent).

Objectives of REsect {#bjs11283-sec-0010}
--------------------

The primary objective was to determine the change in technical resectability of all liver lesions between baseline and time of best treatment response in the liver (defined as the deepest response (nadir) when the sum of the diameters of all hepatic target lesions was lowest).

Subanalyses stratified by the presence or absence of miliary disease in the liver (defined as at least 15 metastases, with reason to assume the patient would remain unresectable after treatment) and by hepatic tumour burden (25 per cent or less or more than 25 per cent) were performed.

Statistical analysis {#bjs11283-sec-0011}
--------------------

All statistical analysis presented here was preplanned. The analysis was performed on an evaluable population that was a subset of the SIRFLOX per protocol population, defined as all patients with evaluable baseline and follow‐up CT results who had received allocated treatment. Analyses from the statistical analysis plan are not presented in their entirety owing to space constraints. Descriptive statistics are provided for patient and disease characteristics at baseline. Change in resectability before and after treatment was tested with the McNemar test, with matched pairs. Agreement based on votes each at baseline and at the time of best response was reported using percentage agreement. Fisher\'s exact test was used for all comparisons except age, body surface area and tumour burden (*t* test). A significance level of *P* \< 0·050 was used in all comparisons.

Results {#bjs11283-sec-0012}
=======

SIRFLOX recruited 530 patients (263 in the control and 267 in the SIRT arm)[21](#bjs11283-bib-0021){ref-type="ref"}. Of these, 472 patients had evaluable baseline and follow‐up imaging, and received the allocated treatment (control, 228; SIRT, 244), forming the population for this analysis (*Fig*. [1](#bjs11283-fig-0001){ref-type="fig"}). The median length of follow‐up was 23·5 months. Baseline characteristics were similar for patients in the two treatment arms (*Tables* [1](#bjs11283-tbl-0001){ref-type="table"} and [2](#bjs11283-tbl-0002){ref-type="table"}).

![CONSORT diagram for the study](BJS-106-1837-g001){#bjs11283-fig-0001}

###### 

Baseline characteristics of patients eligible for the REsect study

                                                                                                    Control arm (*n* = 228)                                SIRT arm (*n* = 244)                    *P* [¶](#bjs11283-note-0002e){ref-type="fn"}
  ---------------------------------------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------
  **Age (years)** [\*](#bjs11283-note-0002a){ref-type="fn"}                                               62·6(10·9)                                            61·8(10·5)                        0·484[\#](#bjs11283-note-0002f){ref-type="fn"}
  **Sex ratio (M** : **F)**                                                                                154 : 74                                              163 : 81                                             0·922
  **Body surface area (m** ^**2**^ **)** [\*](#bjs11283-note-0002a){ref-type="fn"}                        1·87(0·21)                                            1·87(0·22)                        0·884[\#](#bjs11283-note-0002f){ref-type="fn"}
  **Estimated tumour burden (%)** [\*](#bjs11283-note-0002a){ref-type="fn"}           17·6 (15·3)[†](#bjs11283-note-0002b){ref-type="fn"}   18·3 (16·6)[†](#bjs11283-note-0002b){ref-type="fn"}   0·637[\#](#bjs11283-note-0002f){ref-type="fn"}
  **Extrahepatic metastasis**                                                                              91 (39·9)                                             99 (40·6)                                            0·925
  **Hepatic tumour burden (%)**                                                                                                                                                                                       0·416
  ≤ 25                                                                                166 (72·8)[†](#bjs11283-note-0002b){ref-type="fn"}    169 (69·3)[†](#bjs11283-note-0002b){ref-type="fn"}   
  \> 25                                                                                61 (26·8)[†](#bjs11283-note-0002b){ref-type="fn"}     74 (30·3)[†](#bjs11283-note-0002b){ref-type="fn"}   
  **Primary tumour *in situ***                                                                            103 (45·2)                                            108 (44·3)                                            0·854
  **Hepatic miliary disease** [‡](#bjs11283-note-0002c){ref-type="fn"}                                     89 (39·0)                                             94 (38·5)                                            0·925
  **Side of primary tumour**                                                                                                                                                                                          0·100
  Left                                                                                                    177 (77·6)                                            169 (69·3)                       
  Right                                                                                                    46 (20·2)                                             68 (27·9)                       
  Both or unknown                                                                                           5 (2·2)                                               7 (2·9)                        
  **WHO performance status**                                                                                                                                                                                          0·923
  0                                                                                                       149 (65·4)                                            160 (65·8)                       
  1                                                                                                        79 (34·6)                                             83 (34·2)                       
  Missing                                                                                                      0                                                     1                           
  **Bevacizumab** [§](#bjs11283-note-0002d){ref-type="fn"}                                                133 (58·3)                                            122 (50·0)                                            0·079

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d.).

Data unknown for one patient in each arm.

Defined as at least 15 metastases, with reason to assume the patient would remain unresectable after treatment.

Patients who received bevacizumab before disease progression.

SIRT, selective internal radiotherapy; n.d., not done.

Fisher\'s exact test, except

*t* test.

###### 

Baseline characteristics of patients eligible for the REsect study, stratified by absence or presence of miliary disease

                                                                                                No miliary disease (*n* = 289)                        Miliary disease (*n* = 183)                                                                                        
  ---------------------------------------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------- ------------ ------------ -----------------------------------------------
  **Age (years)** [\*](#bjs11283-note-1003a){ref-type="fn"}                                               63·2(11·0)                                           63·0(10·7)                       0·885[§](#bjs11283-note-1003d){ref-type="fn"}   61·6(10·8)   60·0(10·1)   0·330[§](#bjs11283-note-1003d){ref-type="fn"}
  **Sex ratio (M** : **F)**                                                                                90 : 49                                              96 : 54                                             0·903                        64 : 25      67 : 27                         1·000
  **Body surface area (m** ^**2**^ **)** [\*](#bjs11283-note-1003a){ref-type="fn"}                        1·87(0·22)                                           1·86(0·21)                       0·905[§](#bjs11283-note-1003d){ref-type="fn"}   1·89(0·19)   1·89(0·22)   0·941[§](#bjs11283-note-1003d){ref-type="fn"}
  **Estimated tumour burden (%)** [\*](#bjs11283-note-1003a){ref-type="fn"}           13·0(14·1)[†](#bjs11283-note-1003b){ref-type="fn"}   12·9(14·9)[†](#bjs11283-note-1003b){ref-type="fn"}   0·952[§](#bjs11283-note-1003d){ref-type="fn"}   24·8(14·5)   27·0(15·6)   0·941[§](#bjs11283-note-1003d){ref-type="fn"}
  **Extrahepatic metastasis**                                                                             54 (38·8)                                            56 (37·3)                                            0·875                        37 (42)      43 (46)                         0·340
  **Hepatic tumour burden (%)**                                                                                                                                                                                                                                          
  ≤ 25                                                                                116 (84·1)[†](#bjs11283-note-1003b){ref-type="fn"}   124 (83·2)[†](#bjs11283-note-1003b){ref-type="fn"}                       0·875                        50 (56)      45 (48)                         0·655
  \> 25                                                                               22 (15·9)[†](#bjs11283-note-1003b){ref-type="fn"}    25 (16·8)[†](#bjs11283-note-1003b){ref-type="fn"}                                                     39 (44)      49 (52)    
                                                                                                              1                                                    1                                                                                                     
  **Primary tumour *in situ***                                                                            53 (38·1)                                            57 (38·0)                                            1·000                        50 (56)      51 (54)                         0·882
  **Side of primary tumour**                                                                                                                                                                                                                                             
  Left                                                                                                    110 (79·1)                                           100 (66·7)                                                                        67 (75)      69 (73)                         0·560
  Right                                                                                                   27 (19·4)                                            45 (30·0)                                                                         19 (21)      23 (24)    
  Both or unknown                                                                                          2 (1·4)                                              5 (3·3)                                                                           3 (3)        2 (2)     
  **WHO performance status**                                                                                                                                                                                                                                             
  0                                                                                                       95 (68·3)                                            108 (72·5)                                           0·073                        54 (61)      52 (55)                         0·549
  1                                                                                                       44 (31·7)                                            41 (27·5)                                                                         35 (39)      42 (45)    
  Missing                                                                                                     0                                                    1                                                                                0            0       

Values in parentheses are percentages unless indicated otherwise;

values are mean(s.d.).

Data unknown for one patient in each arm. SIRT, selective internal radiotherapy.

Fisher\'s exact test, except

*t* test.

Among the 100 patients reviewed by five surgeons, agreement on resectability/unresectability was 92·1 per cent at baseline and 86·1 per cent at follow‐up. In the study population as a whole, the agreement between reviewers was 100 per cent for 80·4 per cent of patients deemed to have unresectable disease at baseline and around 64·8 per cent at follow‐up. In each treatment arm at baseline and follow‐up, the agreement between the surgeons was 100 per cent for 41·5 per cent of the patients deemed resectable and 80 per cent (4 of 5 reviewers), 60 per cent (3 of 5 reviewers) or 67 per cent (2 of 3 reviewers) for the remainder (*Fig*. [2](#bjs11283-fig-0002){ref-type="fig"}).

![Blinded surgical review panel agreement on resectability at baseline and follow‐up for each patient Percentage agreement on resectability or unresectability in **a,b** control and **c,d** selective internal radiotherapy (SIRT) arms at **a,c** baseline and **b,d** follow‐up. The dotted lines denote the 60 per cent threshold of agreement by the surgical review panel on resectability or unresectability.](BJS-106-1837-g002){#bjs11283-fig-0002}

At baseline there was no statistically significant difference in the technical resectability rate of liver metastases between the SIRT and control arms (11·9 *versus* 11·0 per cent respectively; *P* = 0·775) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *a*). At follow‐up, the technical resectability rate increased significantly in both arms (SIRT: 38·1 (95 per cent c.i. 32·0 to 45·0) per cent, *P* \< 0·001; control: 28·9 (23·0 to 35·0) per cent, *P* \< 0·001). The difference in resectability between SIRT and control arms at follow‐up was also statistically significant (relative risk 1·25, 95 per cent c.i. 1·10 to 1·54; *P* \< 0·001) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *a*). Of patients in the control and SIRT arms deemed unresectable at baseline, 46 of 203 (22·7 per cent) and 67 of 215 (31·2 per cent) respectively, were converted to technical resectability at follow‐up (*P* \< 0·001) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *b*).

![Resectability of colorectal liver metastases Baseline and follow‐up resectability rates in **a** the whole cohort; **b** patients deemed unresectable at baseline; **c** patients with a hepatic tumour burden of 25 per cent or less; **d** patients with a hepatic tumour burden greater than 25 per cent; **e** patients without hepatic miliary disease; **f** patients with hepatic miliary disease.](BJS-106-1837-g003){#bjs11283-fig-0003}

At baseline, in patients with an initial hepatic tumour burden of 25 per cent or less, there was no significant difference in the technical resectability rate of liver metastases between the two treatment arms (*P* = 0·551) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *c*). In both arms the increase in technical resectability from baseline to follow‐up tended to be more pronounced in this population compared with the full data set (SIRT: 49·4 *versus* 17·1 per cent, *P* \< 0·001; control: 34·7 *versus* 14·4 per cent, *P* \< 0·001), and significantly more patients in the SIRT arm with a tumour burden of 25 per cent or less had technically resectable liver metastases at follow‐up than those in the control arm (*P* = 0·008) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *c*). At follow‐up, few patients in either arm with an initial tumour burden greater than 25 per cent were deemed to have technically resectable liver metastases, with no significant difference between the control and SIRT arms (13 *versus* 12 per cent respectively; *P* = 1·000) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *d*).

In patients without miliary disease, the increase in technical resectability rate from baseline to follow‐up tended to be more pronounced in both treatment arms compared with the full data set (SIRT: 54·0 *versus* 19·3 per cent, *P* \< 0·001; control: 45·3 *versus* 18·0 per cent, *P* \< 0·001). At follow‐up, a greater proportion of patients without miliary disease in the SIRT arm (81 of 150, 54·0 per cent) had resectable liver metastases compared with that in the control arm (63 of 139, 45·3 per cent), but the difference was not statistically significant (*P* = 0·158) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *e*). Surprisingly, three of 89 patients (3 per cent) with miliary disease in the control arm and 12 of 94 (13 per cent) in the SIRT arm were considered to have resectable lesions at follow‐up (*P* = 0·029) (*Fig*. [3](#bjs11283-fig-0003){ref-type="fig"} *f*).

In the SIRFLOX study, 70 patients had a resection, some in combination with other local procedures or preoperative hepatic hypertrophy induction (SIRT, 36; control, 34). Forty of these patients were also classified in the REsect study as having technically resectable disease (25 SIRT, 15 control), and 30 patients (11 SIRT, 19 control) as having unresectable disease (*Table* [3](#bjs11283-tbl-0003){ref-type="table"}). All 30 of these patients were deemed to be candidates for complete hepatic tumour clearance through a combination of metastasectomy and one or more additional procedures (such as thermal ablation or preoperative induction of parenchymal hypertrophy).

###### 

Observed resections in SIRFLOX study *versus* assessment of technical resectability in REsect

                                       Technical resectability (REsect)        
  ----------------------------------- ---------------------------------- ----- -----
  **Observed resections (SIRFLOX)**                                            
  Resected                                            40                  30    70
  Unresected                                         119                  283   402
  Total                                              159                  313   472

Discussion {#bjs11283-sec-0013}
==========

REsect showed that in both treatment arms of the SIRFLOX study higher numbers were deemed to be technically resectable after treatment than at baseline. Moreover, the addition of SIRT to the FOLFOX‐based chemotherapy regimen increased the technical resectability rate of metastatic liver lesions at follow‐up.

However, in the SIRFLOX study, as in studies investigating different chemotherapy regimens in patients not selected for potential secondary resectability[26](#bjs11283-bib-0026){ref-type="ref"}, [27](#bjs11283-bib-0027){ref-type="ref"}, there was no difference between treatment arms in the rate of liver resection[21](#bjs11283-bib-0021){ref-type="ref"}. In addition, SIRFLOX did not demonstrate any difference in progression‐free survival at any site between treatment arms. It has been suggested that inadequate patient selection has been partly responsible for these negative results. Patients whose tumours have spread far beyond oligometastatic liver disease may not derive any survival benefit from liver‐directed treatment, whereas benefit may be obtained in patients with earlier disease stages[28](#bjs11283-bib-0028){ref-type="ref"}.

Several reasons may explain the difference between the actual resection rates in SIRFLOX and the technical resectability rate determined in this blinded analysis. Rates of resection are influenced by a range of different factors, such as a patient\'s overall fitness to undergo surgery, access to a specialized hepatobiliary surgical centre, presence and extent of concomitant extrahepatic disease, and the surgeon\'s general attitude and experience. This has also been reported in other studies[29](#bjs11283-bib-0029){ref-type="ref"}, and was seen here. With these factors in mind, many patients in the SIRFLOX study may not have been considered for surgical resection owing to the presence of extrahepatic disease (40 per cent of enrolled patients had extrahepatic metastases and 45 per cent had a primary tumour *in situ*). Moreover, the reluctance of surgeons to operate on livers treated with ^90^Y‐labelled resin microspheres, owing to uncertainties over the safety of such an approach, may also have reduced the resection rate in the SIRT arm of SIRFLOX. Recently published data[30](#bjs11283-bib-0030){ref-type="ref"} have demonstrated that mortality and complication rates in patients undergoing liver surgery after SIRT appeared acceptable given the risk profile of those particular patients; although further data are needed, these results may reassure physicians regarding the feasibility of this approach.

The criterion for resectability in REsect was that the expert HPB surgeons deemed the resection of all visible lesions to be feasible, with negative margins and sufficient FLR size. It is well established, and recommended in treatment guidelines, that the resectability of liver metastases should be assessed by surgeons with extensive experience in HPB surgery. HPB surgeons generally assess more patients as resectable than general surgeons or surgeons from other specialties[31](#bjs11283-bib-0031){ref-type="ref"}, [32](#bjs11283-bib-0032){ref-type="ref"}. This is also why, in studies focusing on chemotherapy for unresectable CRLM, the reported rates of conversion to resectability are extremely heterogeneous. The addition of SIRT to chemotherapy improved the technical resectability rate in the subgroup of patients with a hepatic tumour burden of 25 per cent or less, but not in those with a greater tumour burden. The cutoff of 25 per cent for tumour burden may therefore be useful for selecting patients likely to derive benefit from the addition of SIRT in terms of potential secondary resectability of their liver disease.

A blinded retrospective review of the CELIM trial scans gave similar results to the present study. In the CELIM trial, patients with metastatic colorectal cancer deemed unresectable at baseline by the treating institution received cetuximab with either FOLFOX or FOLFIRI (folinic acid, fluorouracil and irinotecan); the resectability rate, by blinded surgical assessment, increased from 32 per cent at baseline to 60 per cent after treatment[24](#bjs11283-bib-0024){ref-type="ref"}. Despite higher objective tumour response rates in the SIRFLOX study (68·8--78·7 per cent) than in CELIM (57--68 per cent), resectability rates were higher in CELIM. Population differences between these trials probably account for the differences: CELIM focused specifically on conversion to secondary resectability in a potentially curative treatment approach, whereas patients in SIRFLOX were not selected for potential for secondary resectability[21](#bjs11283-bib-0021){ref-type="ref"}.

The limitations of this analysis are those inherent to a *post hoc* analysis. For example, SIRFLOX may not have been powered adequately for such an analysis. Although the blinded approach is useful to remove potential bias, it also obscures clinically important reasons why resection was not performed in specific patients. No attempt was made to correlate the theoretical technical resectability, in the judgement of the panel of HPB surgeons, with any resections performed in patients who participated in the study. However, REsect was designed bearing this in mind, and factors precluding resection other than technical unresectability were disregarded intentionally, as the aim was to evaluate how SIRT might have performed as a conversion treatment in patients who were potential candidates for resection. Given that no formal hypothesis testing was undertaken due to the *post hoc* nature of the analysis, demonstration of clinical significance requires additional validation in an adequately powered sample population.

Nevertheless, the present results provide a rationale for considering the addition of SIRT to FOLFOX‐based chemotherapy (with or without bevacizumab) in such patients, and this approach should be tested in a prospective trial focusing on this population of patients with non‐diffuse, technically unresectable, liver‐only metastatic colorectal cancer who are fit for surgery. The protocol for this trial, with secondary resection rate and disease‐free survival following resection as co‐primary endpoints, is currently in development.

Supporting information
======================
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**Video S1** Training video for assessment of CT scans

###### 

Click here for additional data file.
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